KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time.

The company announced on November 4 that its self-developed CM512, the world's first long-acting TSLP x IL-13 bispecific antibody, achieved all primary endpoints in its Phase I clinical trial for moderate-to-severe atopic dermatitis (AD) in adults.

Clinical data demonstrated CM512's rapid disease control, deep remission, and sustained efficacy in treating moderate-to-severe AD patients, with a favorable safety profile and an extended half-life of 70 days. These results suggest its potential as a best-in-class therapy for adult AD.

CM512 is KEYMED BIO's proprietary IgG-like bispecific antibody that simultaneously targets TSLP and IL-13. It works by early suppression of inflammatory cascade initiation, effectively reducing Th2 cell differentiation and IL-13 cytokine release while directly inhibiting IL-13-driven pathological symptoms, offering enhanced treatment for type 2 inflammatory diseases.

The company is accelerating Phase II trials for CM512 across multiple indications including AD, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.